Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
iSpecimen ( (ISPC) ) just unveiled an update.
On December 31, 2025, iSpecimen Inc. convened its 2025 Annual Meeting of Stockholders but adjourned it due to a lack of quorum, a problem that recurred when the meeting was reconvened on January 23, 2026, February 13, 2026, and March 13, 2026. The company now plans to reconvene the meeting on April 10, 2026, maintaining November 3, 2025 as the record date and leaving the slate of proposals unchanged, underscoring ongoing challenges in securing sufficient shareholder participation for corporate governance decisions.
The repeated adjournments indicate that iSpecimen is experiencing difficulties in mobilizing its shareholder base, which may delay approvals related to its strategic, governance, or compensation matters outlined in the proxy. This pattern can create operational uncertainty and may signal weaker investor engagement, potentially affecting how the company executes its plans and is perceived in the public markets.
The most recent analyst rating on (ISPC) stock is a Sell with a $0.34 price target. To see the full list of analyst forecasts on iSpecimen stock, see the ISPC Stock Forecast page.
Spark’s Take on ISPC Stock
According to Spark, TipRanks’ AI Analyst, ISPC is a Neutral.
The score is weighed down primarily by weak financial performance (sharp TTM revenue decline, margin deterioration, ongoing losses, and persistent cash burn). Technicals add a mixed-to-weak backdrop (below key longer-term moving averages with negative MACD). Corporate events and valuation provide limited offset given Nasdaq bid-price compliance risk and a negative P/E tied to ongoing losses.
To see Spark’s full report on ISPC stock, click here.
More about iSpecimen
iSpecimen Inc. operates in the life sciences and healthcare research industry, providing a marketplace platform that connects researchers with human biospecimens sourced from a network of hospitals, laboratories, and biobanks. The company focuses on streamlining access to specimens needed for medical research, diagnostics development, and related scientific studies, serving pharmaceutical, biotech, and academic customers.
Average Trading Volume: 2,328,938
Technical Sentiment Signal: Strong Sell
Current Market Cap: $2.19M
Find detailed analytics on ISPC stock on TipRanks’ Stock Analysis page.